Five things for pharma marketers to know: Wednesday, June 21, 2017

Share this content:

1. While PCSK9 inhibitors can dramatically reduce levels of bad cholesterol, insurance companies are balking at paying for them. List prices usually exceed $14,000 per year. (WSJ)

2. Publicis Groupe said it plans to take a year off from promotional investments, such as the Cannes Lions International Festival of Creativity. It will instead focus spending on  a new AI-powered professional-assistant platform designed to foster better communication among its 80,000 employees across 130 countries. (Ad Age)

3. In late-stage clinical trials conducted by Novartis, the drugmaker's experimental eye drug RTH258 required injections every 12 weeks for patients with neovascular age-related macular degeneration. By comparison, Regeneron's Eylea requires doses every eight weeks. (Reuters)

4. Shire received FDA approval for its long-acting attention-deficit drug Mydayis. The new treatment lasts up to 16 hours, four hours longer than the drugmaker's other widely used ADHD drug Adderall XR. (Reuters)

5. Nearly 1.3 million Americans required hospitalization in 2014 for treatment related to opioid abuse. The number of emergency room visits has increased 99% since 2005, according to a new report. (WaPo)

Share this content:
Scroll down to see the next article